MDLinx, a division of M3 USA, announced today a new Omnibus offering for
international pharmaceutical market research. The new offering, launched
at the Pharmaceutical Market Research Conference, enables market
researchers a new, simplified, reduced-cost means of accessing specialty
physicians around the world. Eight Omnibus products are offered in the
most difficult to reach specialties including Oncology (Oncobus),
Rheumatology (Rheumbus), Psychiatry (Psychbus), Neurology (Neurobus),
Endocrinology (Endobus), Cardiology (Cardiobus), Infectious Disease
(IDbus) and General Medicine (GPbus). The omnibus surveys are run
monthly and pool together questions from participating research
companies. The pooled approach means researchers can access physicians
at lower cost and higher frequency. Companies participating in the
Omnibus can ask as few as three questions. Pharmaceutical companies can
now efficiently and quickly access 350 specialty physician responses
from around the world including the USA, Japan, Germany, France, UK,
Spain, and Italy. All of the physician respondents are from MDLinx’s MRA
Verified worldwide panel – the largest verified healthcare professional
panel in the world.
“Our
unsurpassed reach and exclusive deep relationships with physician
specialists in the USA, EU, and Japan allow us to be the only company to
offer a monthly worldwide omnibus in these specialties.”